BioCentury
ARTICLE | Company News

BioAtla, Beijing Sinobioway deal

February 1, 2016 8:00 AM UTC

BioAtla received $19 million in undisclosed program payments and an undisclosed equity investment from Sinobioway under a May 2015 deal granting Sinobioway exclusive rights to develop and commercialize preclinical mAb, antibody-drug conjugate and chimeric antigen receptor (CAR) T cell products using BioAtla’s Conditionally Active Biologic (CAB) platform in Taiwan and China, including Hong Kong and Macau. ...